Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug BI 765883 tested in pancreatic cancer – early trial ends

NCT ID NCT06528093

Terminated Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This early study tested an experimental drug called BI 765883, alone or with chemotherapy, in 8 adults with advanced pancreatic cancer. The goal was to find a safe dose and see if it helps shrink tumors. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BI 765883 (an experimental drug) given alone or with gemcitabine and nab-paclitaxel chemotherapy
What this could lead to
If it works, this could point toward a new treatment option for advanced pancreatic cancer.
What could go wrong
This is a very early, small trial (only 8 people) that was terminated, so results are limited. The drug may not be effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

  • CTR Eugène Marquis

    Rennes, 35042, France

  • CTR Leon Berard

    Lyon, 69373, France

  • Cliniques Universitaires Saint-Luc

    Brussels, 1200, Belgium

  • Florida Cancer Specialists-Sarasota-61670

    Sarasota, Florida, 34232, United States

  • HealthONE

    Denver, Colorado, 80218, United States

  • Hospital Clínic de Barcelona

    Barcelona, 08036, Spain

  • Hospital Universitario Ramon Y Cajal

    Madrid, 28034, Spain

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Klinikum der Universität München AÖR

    München, 81377, Germany

  • National Cancer Center Hospital

    Tokyo, Chuo-ku, 104-0045, Japan

  • National Cancer Center Hospital East

    Chiba, Kashiwa, 277-8577, Japan

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • UZ Leuven

    Leuven, 3000, Belgium

  • Universitätsklinikum Hamburg, Eppendorf

    Hamburg, 20246, Germany

  • Universitätsklinikum Heidelberg

    Heidelberg, 69120, Germany

  • Yale Cancer Center

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.